About: The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis
Creator	Li, Sun Wang, Cao Ji, Guangcheng Li, Jiannan Qi, Xun Song, Bailin Sun, Shaoqian Sun, Yihan Wang, Yufeng Xu, Xiaohong Zhang, Qiongshuai
Source	Medline; PMC
abstract	BACKGROUND: Currently, the global number of infected novel coronavirus has exceeded 2.6 million and the death toll has exceeded 170,000, but the specific drug for the treatment of COVID-19 has been not appears. In the process of fighting COVID-19 in China, JHQG has been promoted by the Chinese government and widely used in the treatment of COVID-19. The purpose of this study is to systematically evaluate the efficacy and safety of JHQG for COVID-19. METHODS: We are going to search the electronic databases: PubMed, EMBASE, Cochrane library, Web of Science (WOS), Google scholar, China National Knowledge Infrastructure (CNKI), Chinese Biomedical literature Database (CBM), Chinese Scientific and Journal Database (VIP), Wan Fang database (Wanfang) for published clinical trails and search clinical trials register platforms of Chinese Clinical Trial Registry (ChiCTR) and ClinicalTrials.gov (www.ClinicalTrials.gov/) for ongoing trials of Jinhua Qinggan granule for COVID-19. The primary outcomes of the included studies contain Clinical symptom disappearance rate and the secondary outcomes obtain: TCM syndrome scale score, Hamilton anxiety scale score, and adverse events. We will use RevMan V5.3 software to perform the calculations. PRISMA-P checklist was used in writing this report. RESULTS: The study results will be submitted to a peer-reviewed journal for publication. CONCLUSION: This study will provide a high-quality evidence of the efficacy and safety of Jinhua Qinggan granule on patients with COVID-19. PROSPERO REGISTRATION NUMBER: CRD42020181919.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1097/md.0000000000020531
bibo:pmid	32541475
has license	cc-by
sha1sum (hex)	e09ce924c516c57a9630452f776e3805265b6ac1
schema:url	https://doi.org/10.1097/md.0000000000020531
resource representing a document's title	The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis
has PubMed Central identifier	PMC7302627
has PubMed identifier	32541475
schema:publication	Medicine (Baltimore)
resource representing a document's body	covid:e09ce924c516c57a9630452f776e3805265b6ac1#body_text
is schema:about of	named entity 'Biomedical' named entity 'COVID-19' named entity 'Chinese' named entity 'evaluate' named entity 'specific' named entity '170' named entity 'REGISTER' named entity 'NOVEL CORONAVIRUS' named entity 'SAFETY' named entity 'DATABASES' named entity '2.6' named entity 'CHINA' named entity 'WOS' named entity 'database' named entity 'drug' named entity 'CBM' named entity 'CNKI' named entity 'The' named entity 'published' named entity 'Wanfang' named entity 'COVID-19' named entity 'COVID-19' named entity 'Clinical Trial' named entity 'CNKI' named entity 'database' named entity 'Study Protocol' named entity 'confidence intervals' named entity 'ClinicalTrials.gov' named entity 'COVID-19' named entity 'COVID' named entity 'sars-cov-2' named entity 'Web of Science' named entity 'heterogeneity' named entity 'PubMed' named entity 'epidemic' named entity 'COVID 19' named entity '2.6 million' named entity 'dyspnea' named entity 'placebo' named entity 'Statistical heterogeneity' named entity 'control group' named entity 'EMBASE' named entity 'COVID' named entity 'Clinical symptom' named entity 'Clinical Trial' named entity 'Randomized controlled trials' named entity 'COVID' named entity 'missing data' named entity 'WOS' named entity 'heterogeneity' named entity 'COVID' named entity 'relative risk' named entity 'Chinese herbal medicine' named entity 'COVID' named entity 'sample size' named entity 'COVID' named entity 'TCM' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'pneumonia' named entity 'Chinese herbal medicines' named entity 'e-mail' named entity 'Chinese central government' named entity 'allocation concealment' named entity 'Wuhan' named entity 'experimental group' named entity 'COVID' named entity 'adverse events' named entity 'COVID-19' named entity 'reporting bias' named entity 'COVID' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software